# Pizarra — PT-pseudo_33c8cd4571fd (task 1)

---

# Ronda 1

## [1] CASE FILE

**INTAKE** — *the patient record, verbatim; adds no interpretation*

The structured clinical record below is the read-only panel the urologist sees up front, exactly as it arrives in this patient's record. The documents it refers to are masked and must be retrieved.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_33c8cd4571fd
Task: 1

Encounter: Urology - outpatient on 01 Mar 2025.
Referrer: Dr. M. Jansen (GP).
Type: Follow-up - PSA + MRI.

Clinical data (read-only — values loaded from the record):
  - 71-year-old male
  - PSA: 12.0 ng/mL
  - mpMRI — PI-RADS score: 5 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.411 ng/mL²
  - PSA velocity: 0.96 ng/mL/yr
  - Prior PSA: 11.0 ng/mL
  - Prostate volume: 29.2 mL
  - Months since last PSA: 1
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: None (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.884623 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Hypertension
  - Problem list / PMHx: Hypertension
  - Current medication: valsartan, lisinopril, metoprolol
  - Allergies: NKA
  - Additional notes: PSA 12 ng/mL. PI-RADS 5. PSAD 0.41. Prostate volume 29 mL. csPCa 0.88.

Vitals: weight 64 kg, height 177 cm, BMI 20.4, BP 140/87 mmHg, HR 59 bpm. Smoking: Non-smoker.

Chief complaint: Persistent PSA elevation necessitated a scheduled MRI review.

History: At 71 years old, the retired primary school teacher has tracked a gradual PSA rise since late 2022, calculating a velocity of 0.96 ng/mL annually. Residing with his wife, he stays active through daily twenty-minute walks and light gardening. Lower urinary complaints sit at a moderate 12 on the IPSS, dominated by nocturia and a diminished stream, handled without intervention. Fifteen alcohol units are consumed each week. Haematuria, pelvic discomfort, and unexplained weight loss are denied. Well-controlled hypertension relies on valsartan, lisinopril, and metoprolol, with cardiology parameters remaining stable. Recent podiatry for nail care and a standard hearing assessment both returned unremarkable. He does not smoke, reports steady energy, and experiences no sleep disturbances. Clinical records note a prior biopsy bucket of None.

Physical examination: DRE: The prostate presents as symmetrically smooth, lacking palpable nodules or asymmetry, aligning with a normal assessment. General inspection shows a well-nourished individual (BMI 20.4), blood pressure reading 140/87 mmHg, and a regular pulse of 59 bpm. Peripheral oedema and lymphadenopathy are absent.

Patient info: retired primary school teacher; Married; Lives with partner.
Next of kin: Adult daughter (primary contact).

Lifestyle: alcohol 15 units / week; exercise Walking 20 min/day; IPSS score: 12/35 (moderate LUTS).

Recent other appointments: Podiatry — routine foot care; Audiology — hearing test.
Admin: Interpreter: not required. Consent for data use: signed.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


[Note for the conference: for a task-1 biopsy decision only FOUR masked documents exist on file - the radiology / mpMRI report, the PSA history, the previous notes and the laboratory panel - plus the family-history anamnesis. There is no pathology report to retrieve for this task; the prior-biopsy status in the panel above is all the pathology information on record.]

## [2] STATISTICAL PRIOR (classifier)

**EXPERT-PRIOR** — *statistical expert; bagged classifier over the structured panel, trained on the labelled cohort, out-of-fold honest*

A basic classifier, whose sole purpose is to provide a suggestion, produces this result along with its associated uncertainty. The purpose of this decision is to use it as an initial reference point for discussing the results.

SUGGESTION: BIOPSY
  p(biopsy = yes) = 0.95 +/- 0.03   (95% CI 0.89-1.00)

Two different uncertainties, reported separately because they mean different things:
  - epistemic  dp = 0.03  — the error bar on this number. It is the spread
    across bootstrap members: how much the answer would move with a different training sample.
  - aleatoric  H  = 0.29 of 1.00 — how mixed the outcome was among
    patients this model cannot tell apart. High H means the disagreement is in the data, not in
    the model, and more labelled cases would not fix it.

TIER 'firm': p +/- 1.96*dp does not cross the 0.5 threshold. Treat it as a strong prior that should only be overturned by explicit contradicting evidence. Measured accuracy in this tier on the labelled cohort: 1.0 over 28 cases.

Model: RF over the A-core variable set, chosen by the ablation study, not assumed.
Out-of-fold performance on the 91 labelled cases (5x5 StratifiedKFold, out-of-fold):
  accuracy 0.714 (majority-class baseline 0.615), AUC 0.789, F1(yes) 0.78.
Variables it could not read for this patient: none.

It has read ONLY the structured panel and the parsed record. It has not reasoned about the
prose of the mpMRI report, and it does not know what this patient's management plan is.

## [3] GUIDELINE CRITERION FOR THIS SITUATION

**EXPERT-PROTOCOL** — *protocol expert; applies the guideline criterion for this patient's clinical situation*

CLINICAL SITUATION: biopsy-naive.

CRITERION VERDICT: BIOPSY.

The criterion: Biopsy when the mpMRI shows a PI-RADS 3 or higher lesion; defer when PI-RADS is 1-2.

In the labelled cohort this criterion matched the reading urologist in every one of the 24 biopsy-naive cases (20 of them PI-RADS 4-5 and biopsied, 4 of them PI-RADS 2 or unreadable and deferred).

Track record of this criterion on the labelled cohort: 24 of 24 cases matched the reading urologist. Departing from it needs a specific finding from a retrieved document, named explicitly - not a restatement of the panel numbers it already used.

Like the statistical prior, this expert has read ONLY the visible panel. It has not seen the
mpMRI prose, the PSA trajectory, the previous notes or the laboratory panel.

## [4] IMAGE-EMBEDDING PREDICTOR

**EXPERT-IMAGE** — *image-embedding expert; frozen foundation-model MRI vectors behind a trained head*

Frozen foundation-model embeddings on file for this patient: MRI image (1 vector).
The raw vectors are never shown; only a compact score would be.

No calibrated head is deployed for the biopsy decision, so no score was produced. The probe that measured this modality for task 1 reported AUC 0.43 (at or below chance), which is why nothing is being asserted here.

Bottom line for the chair: the image-embedding route contributes NO usable evidence for this
biopsy decision. Decide on the structured panel, the retrieved documents and the guidelines.
Do not cite imaging-embedding support in the reasoning, and do not let the absence of a score
count as a negative finding.

## [5] AGENDA (round 1)

**MODERATOR** — *moderator; owns the agenda and decides whether the conference may close*

AGENDA FOR ROUND 1. These are the documents this case needs opened, and the question each one must answer. Open these and nothing else unless a named question requires it.

  - radiology_report (get_mri_report) -> Does the mpMRI show a PI-RADS 3 or higher lesion?
  - psa_trend (get_psa_trend) -> Is the PSA trend significant enough to warrant immediate action?
  - previous_notes (get_previous_notes) -> What is the prior management context and agreed-upon surveillance pathway?

This case hinges on the findings of the mpMRI and the trajectory of the PSA, as the statistical prior and protocol suggest a high probability of biopsy. We must retrieve the specific details from the radiology report, PSA history, and previous notes to confirm the protocol criteria.

## [6] GAPS AND DOUBTS (round 1)

**LLM-1-GAP-ANALYST** — *raises doubt only; has no access to clinical documents and issues no recommendation*

WHAT THE PRIOR CANNOT SEE
The statistical prior only weighed the structured panel, which includes PSA (12.0 ng/mL), PI-RADS (5), PSA density (0.411 ng/mL²), PSA velocity (0.96 ng/mL/yr), and prior biopsy status (None). It cannot weigh the qualitative information from the mpMRI prose, the specific PSA trajectory details beyond the headline velocity, or the context provided in the previous notes regarding the management plan.

WHY THE SUGGESTION COULD BE WRONG
The prior suggests a high probability of biopsy (p=0.95), but the protocol states biopsy is indicated for PI-RADS $\ge 3$, which is met (PI-RADS 5). However, the guideline text notes that the NPV of MRI decreases in high-risk populations, suggesting the model might be over-relying on the PI-RADS score without fully accounting for the clinical context or the uncertainty in the MRI interpretation. The high aleatoric uncertainty ($H=0.29$) indicates the data itself is highly mixed, meaning the model's confidence in the 0.95 probability is based on a highly variable patient population.

WHAT TO RETRIEVE, AND WHAT WOULD CHANGE THE ANSWER
radiology report - Does the mpMRI show a PI-RADS 3 or higher lesion?
psa_trend - Is the PSA trend significant enough to warrant immediate action?
previous_notes - What is the prior management context and agreed-upon surveillance pathway?
laboratory panel - What are the full laboratory results?

GUIDELINE ANCHOR
The guideline states that a PI-RADS threshold of $\ge 3$ is used to trigger biopsy, and MRI-directed biopsy is the standard of care.

## [7] EVIDENCE REPORT (round 1)

**LLM-2-EVIDENCE** — *the only participant who retrieved documents; reports findings, not verdicts*

RETRIEVED
get_mri_report
MRI report: PI-RADS 5 lesion in the left peripheral zone (approx. 12x8x10 mm) with restricted diffusion and early, intense enhancement. csPCa predicted probability 0.884623.
get_psa_trend
PSA trend: Shows a rising trajectory from 3.6 ng/mL in Sep 2022 to 12.0 ng/mL in Mar 2025.
get_previous_notes
Previous notes: On 01 Nov 2024, a review occurred after PSA climbed to 11.0 ng/mL in July, prompting scheduling of an mpMRI.

NOT RETRIEVED
get_lab_results
The full laboratory panel was not retrieved because the moderator's agenda did not explicitly require it, and no immediate question arose from the retrieved documents.

WHAT THE EVIDENCE SUPPORTS
FOR sampling this patient now:
- MRI report: PI-RADS 5 lesion in the left peripheral zone.
- PSA trend: Significant rising trajectory from 3.6 ng/mL (Sep 2022) to 12.0 ng/mL (Mar 2025).
- Previous notes: Context confirms the MRI was scheduled due to persistent PSA elevation.

AGAINST sampling this patient now:
- DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done).

WHERE THIS LEANS
The evidence strongly supports biopsy due to the PI-RADS 5 finding and the significant PSA velocity, confirming the statistical prior.
LEAN: biopsy

[Opened in this round: radiology_report, psa_trend, previous_notes. Open on the board so far: radiology_report, psa_trend, previous_notes.]

## [8] CLOSING CHECK (round 1)

**MODERATOR** — *moderator; owns the agenda and decides whether the conference may close*

THE CONFERENCE MAY CLOSE.

Positions on the table: prior=yes, protocol=yes, evidence=yes.
Consensus: yes — unanimous among those who took a position.
Agenda: requested ['radiology_report', 'psa_trend', 'previous_notes']; opened ['radiology_report', 'psa_trend', 'previous_notes']; still missing nothing.

The retrieved evidence (PI-RADS 5 lesion and significant PSA trend) strongly supports the protocol criterion for biopsy. The record is sufficient to proceed to the final decision stage, although the full lab panel remains unretrieved.

The chair decides on the record as it stands.

## [9] FINAL DECISION AND FORM

**LLM-3-CHAIR** — *chairs the conference; the only participant who decides*

FINAL DECISION: BIOPSY   (confidence: clear)

The decision to biopsy is supported by convergence across all inputs. The PI-RADS 5 finding from the mpMRI was decisive, aligning with the guideline criterion for biopsy when PI-RADS is 3 or higher. This was reinforced by the significant PSA trend, rising from 3.6 ng/mL to 12.0 ng/mL, which was retrieved evidence. The statistical prior also strongly suggested biopsy, leading to a clear consensus.

Variables that carried weight: age=important, psa=important, vol=noted, psad=important, pirads=decisive, comorbidity=noted
Sections revealed: radiology_report, psa_trend, previous_notes
